Gain Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 32
- Market Cap
- -
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)β’ Click on a phase to view related trials
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Gain Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06732180
- Locations
- π¦πΊ
St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
π¦πΊSouthern Neurology, Kogarah, New South Wales, Australia
π¦πΊWestmead Hospital, Westmead, New South Wales, Australia
News
Gain Therapeutics to Present Phase 1 Data for Novel Parkinson's Drug GT-02287 at MJFF Conference
Gain Therapeutics will present Phase 1 results for GT-02287, their brain-penetrant small molecule drug candidate for Parkinson's disease, at the Michael J. Fox Foundation's 16th Annual Conference.
Gain Therapeutics' GT-02287 Enters Phase 1b Trial for Parkinson's Disease
Gain Therapeutics has initiated a Phase 1b clinical trial in Australia for GT-02287, targeting both idiopathic and GBA1-linked Parkinson's disease.
Gain Therapeutics' GT-02287 Shows Promise in Phase 1 Trial for Parkinson's Disease
Gain Therapeutics announced positive topline results from its Phase 1 clinical trial of GT-02287, a novel small molecule therapy targeting GCase for Parkinson's disease.